Skip to content
Screener

Emergent Biosolutions EBS Q4 2025 Annual earnings

Reported February 26, 2026 · After market close

Revenue$148.7MMiss by $68.8M
EPS-$0.43Miss by $0.54
Revenue estimate$217.5M
EPS estimate$0.11

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$123.2M
EPS estimate-$0.37

Financials

Q4 2025

Income statement

See full
Revenue$148.7M-23.6%
Gross profit$63.8M-16.8%

Balance sheet

See full
Cash & equivalents$209.1M+98.0%
Total debt$583.7M-13.7%
Total equity$522.6M+8.2%
Total assets$1.3B-5.1%

Cash flow

See full
Operating cash flow$77.7M—
CapEx$3.9M+129%
Free cash flow$73.8M—

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$649.15M+25.3%
Enterprise value$1.02B-5.9%
P/S0.9×+0.4×

Profitability

See full
Gross margin56.1%+21.4pp
FCF margin21.9%—

Returns & leverage

See full
Debt / equity1.1×-0.3×
Current ratio5×+1.3×

Segments

By segment

See full
MCM Products$99.2M-15.1%
Commercial Products$38.4M-41.0%

FAQ

When did Emergent Biosolutions report Q4 2025 earnings?
Emergent Biosolutions (EBS) reported Q4 2025 earnings on February 26, 2026 after market close.
What were Emergent Biosolutions's Q4 2025 revenue and EPS?
Emergent Biosolutions reported revenue of $148.7M and eps of $-0.43 for Q4 2025.
Did Emergent Biosolutions beat estimates in Q4 2025?
Revenue missed the consensus estimate of $217.5M by $68.8M. EPS missed the consensus estimate of $0.11 by $0.54.
How did Emergent Biosolutions's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 21.4% from $189.3M a year earlier.
Where can I find Emergent Biosolutions's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001367644-26-000012) and the 10-K periodic report (0001367644-26-000015) directly on SEC EDGAR. The filing index links above go to sec.gov.